






















































































General Thoracic Surgery Lee et al
1
G
TS6. Okada M, Yoshikawa K, Hatta T. Is segmentectomy with lymph node
assessment an alternative to lobectomy for non–small cell lung cancer
of 2 cm or smaller? Ann Thorac Surg. 2001;71:956-61.
7. Port JL, Andrade RS, Levin MA, Korst RJ, Lee PC, Becker DE, et al.
Positron emission tomographic scanning in the diagnosis and staging
of non–small cell lung cancer 2 cm in size or less. J Thorac Cardio-
vasc Surg. 2005;130:1611-5.
8. McKenna RJ Jr, Houck W, Fuller CB. Video-assisted thoracic surgery
lobectomy: experience with 1,100 cases. Ann Thorac Surg. 2006;81:
421-6.
9. Kaseda S, Aoki T. Video-assisted thoracic surgical lobectomy in
conjunction with lymphadenectomy for lung cancer J Jpn Surg Soc.
2002;103:717-21.
0. Lewis RJ, Caccavale RJ. Video-assisted thoracic surgical non–rib
spreading simultaneously stapled lobectomy (VATS(n)SSL) Semin
Thorac Cardiovasc Surg. 1998;10:332.
1. McKenna RJ Jr, Fischel RJ, Wolf R, Wurnig P. Is VATS lobectomy an
adequate cancer operation? Ann Thorac Surg. 1998;66:1903-8.
iscussion
r Daniel L. Miller (Atlanta, Ga). Dr Lee, I congratulate you and
our colleagues at Cornell for your continued refinement in CT
creening and treatment of early-stage lung cancer.
I have three questions. I was impressed by your cytopatholo-
ists and interventional radiologists who achieved a diagnosis by
ne-needle aspiration on 58% of your patients with a subcentime-
er nodule, but also I was disappointed that 45% of your patients
nderwent a PET scan for a 1 cm or less nodule that was nondi-
gnostic 41% of the time. What is your institution’s current algo-
ithm for the workup of a subcentimeter pulmonary nodule?
Dr Lee. We do not generally obtain PET scans for subcenti-
eter nodules. Unfortunately, most of the patients we see in the
ffice have already had a PET scan that was ordered by the
eferring physician.
In terms of workup for subcentimeter nodules, we are very
rivileged to have a very good interventional radiologist who can
eedle a lot of these subcentimeter tumors. That is probably not
rue in other institutions. Fifty-eight percent of our patients had
issue diagnosis obtained by fine-needle aspiration before resec-
ion. As part of our workup, we examine previous x-ray films or
T scans. If the nodule is a new growth, if it has suspicious CT
ndings of solid lesion and spiculation in someone who is older
ith a smoking history, then we proceed to fine-needle aspiration.
f the nodule is not otherwise suspicious, we are inclined to
onitor the patient by CT scan in 6 months or a year. I can tell you
rom our experience that we do not routinely order PET scans to
ork these nodules up, again, because of the data indicating high
alse negative results by PET scan in detecting subcentimeter
umors.
Dr Miller. My second question is in two parts and it concerns
he histologic type of your tumors. Eighty-two percent of the
umors are either adenocarcinoma and/or bronchoalveolar carci-
oma. In your study was there any difference in survival based on
he histologic type? If so, was this difference related to nodal
nvolvement because of the histologic type?
Dr Lee. We did not see any differences in survival among the
ifferent cell types. As you mentioned, 82% of the patients had
denocarcinomas, so the number of squamous cell cancers and
arge cell cancers is small in our study. The only survival differ-
nce that we noticed was among different stages, for example,
tage IA versus non-IA. s
388 The Journal of Thoracic and Cardiovascular Surgery ● DecDr Miller. You had an outstanding 5-year and 10-year survival
or your lung cancer deaths only for stage IA. How many of those
atients had bronchoalveolar cancer? Such a high survival is very
imilar to the Japanese data.
Dr Lee. Nine patients had bronchoalveolar cancer in that
roup.
Dr Miller. And they were all in the IA group?
Dr Lee. Correct.
Dr Miller. Finally, 12% of your patients underwent a limited
esection, either a wedge or segmentectomy. You found that there
as no difference in survival based on the type of resection, and
his is probably related to the small number in that subset. What are
our institution’s current recommendations for the type of resec-
ion and the approach for these subcentimeter lung cancers, and
specially in regard to bronchoalveolar cancer?
Dr Lee. Our institution has undergone a shift in terms of doing
ore and more thoracoscopic lobectomies over the past 3 or 4
ears. The gold standard is still a lobectomy among good-risk
atients. We need a large prospective randomized study looking at
imited resection versus lobectomy to be able to fully answer that
uestion. As it stands right now, if a patient is at good risk with a
ood performance status, we offer the patient a lobectomy. Now,
f the patient has medical comorbidities or limited functional
tatus, I think it is very reasonable to offer a limited resection.
lthough we had only 2 patients with N2 metastases, we did have
patients with intralobar satellites. The disadvantage of a limited
esection is that you might miss the intralobar satellite lesions.
ntil we have the results of a large prospective randomized study,
e do not have the full answer yet. As it stands right now, we do
erform a lot of thoracoscopic lobectomies, and the only time we
erform limited resection is for very small peripheral tumors and
n someone who has poor performance status or limited pulmonary
unctions. There are also some studies suggesting that non-solid or
ronchoalveolar cancer lesions might be more amenable to limited
esection. We are looking at those questions and others with Dr
ltorki.
Dr Darroch W. O. Moores (Albany, NY). Do you have any
ata on second primaries in this long follow-up, and if the patients
ad secondary primaries, did they have second operations?
Dr Lee. We did not look specifically at second primaries. We
oted 5 recurrences overall in the patients with non-IA disease.
here were also several patients in our series who had previous
obectomies for lung cancer. They were 6 or 7 years out from the
rst operation when their current second primary tumors devel-
ped.
Dr Jack A. Roth (Houston, Tex). Dr Lee, you mentioned that
1 of your patients were in the ELCAP study, so the lesion was
icked up with screening, is that correct?
Dr Lee. Correct.
Dr Roth. Presumably the others were all incidental findings.
hat percent of those 21 patients actually had stage IA disease,
nd did you see any differences in survival in that group versus the
atients who had the lesions picked up incidentally?
Dr Lee. Eighty-six percent of that group of 21 patients had
tage I disease. There was only 1 patient in that group with N2
isease. We did not see any differences in survival between that
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TSDr Frank C. Detterbeck (New Haven, Conn). You corroborate
hat a number of other people have shown, that even for subcen-
imeter lesions there is a fairly high incidence of N1 nodal in-
olvement or of other tumors in the lung, so that you should really
o a lobectomy, even if it is a subcentimeter lesion. I think the PET
can data are also interesting. Again, they corroborate what others
ave shown, at least if we look at PET scans by the usual,
onventional approaches, although there may be newer approaches
o look at these scans that may be better. Your data in conjunction
ith a paper we just heard earlier about the low survival in the
urveillance Epidemiology and End Results database means that
e should deplore what happens in the real world, where a small
esion is seen by a nonthoracic surgeon and the temptation to do a
edge resection is very strong and that is all that is done.
My question to you is this: there are actually fair amounts of
ata that nonsolid lesions have a low incidence of nodal involve-
ent and a low incidence of any other invasion and can perhaps be
ppropriately treated by a wedge resection. Did you look at that in
our dataset? How many of these were nonsolid lesions and what
as the incidence of nodal involvement? Are those perhaps pa-
ients who can be treated by less than a lobectomy?
Dr Lee. That is a very good question. When we looked back at
ur current series at which patients had ground-glass opacity
ithout any solid component, we did have 15 patients that radio-
raphically had ground-glass opacity based on the report. We do
ot have the outcome data in terms of all patients presenting to us
ith ground-glass opacity measuring 1 cm or less. I think that is a
ery interesting point and something we can look into in the future.
eep in mind that our current study is a surgical series, and the
ay we did our initial search was to look at pathologic tumors 1
m or less in size that have been resected.
Dr John Howington (Cincinnati, Ohio). With your outstand-
ng survivals among these patients with 1 cm lesions and your
revious experience with lung cancer screening, are you now
outinely recommending screening among the families of these
ndividuals with early-stage lung cancers who are smokers? Spe-
ifically, are you advocating to the community that they should
ndergo lung cancer screening?
Dr Lee. That is a very controversial topic. Clearly, among the
1 patients who were in screening, 76% of those patients were
tage IA and were found to have high curability of these tumors.
f your tumor is picked up in a subcentimeter level and is indeed
n stage IA, you know from our data that you are essentially cured
f the disease. However, I am not going to go into the downside of
creening, as well as the cost involved. I am a firm believer in
creening. I have a father who smokes and I pay out of my pocket
o get him a CT scan every year. c
The Journal of ThoracicDr Altorki. I just have a comment. I would caution that we do
ot draw one conclusion one way or the other with respect to the
fficacy of lesser resections in these subcentimeter tumors.
learly, the impediment to doing a lesser resection here is mainly
he presence of intralobar satellites, which occurred in roughly 5%
f the patients in this particular series. One can make the argument
hat 95% of the patients could have been adequately treated by a
esser resection. What we really need is a random assignment trial
hat would answer that question. This study in no way supports
oing it one way or the other. Dr Miller’s question is, what do we
o? Well, what I do is that if I have somebody with a peripheral
ubcentimeter lesion, I offer the option of a segmentectomy.
Dr Joseph S. Friedberg (Philadelphia, Pa). Did those needle
iopsies change your management, and did you have any that were
alse negatives that you subsequently followed and turned out to be
ositive? We would not normally do a needle biopsy if it looked
ike a suspicious lesion, which seemed to be your criterion. And
ust an observation: Do you have an explanation for the prepon-
erance of women in your lung cancer population?
Dr Lee. All of the 48 tumors initially diagnosed by needle
iopsy subsequently had pathology-proven confirmation after re-
ection, so we did not have any false positive needle biopsies. In
erms of false negative results, I do not have the answer to that in
erms of this series. Again, our institution is a little skewed in that
e do have a superb interventional radiologist who can needle
hese lesions and we have an on-site cytopathologist who looks at
he adequacy of the specimen. I think without having him, prob-
bly more patients would have gone to the operating room for a
iagnostic wedge resection. It does help in terms of planning the
peration and discussion with the patient that we have a tissue
iagnosis before the surgery. Some of these tumors are quite deep
nd it is hard to palpate thoracoscopically. If we have the needle
iagnosis and we have a lot of confidence in the diagnosis, we go
traight to a thoracoscopic lobectomy. We do not have to wedge
ut the lesion intraoperatively and wait to get a diagnosis by frozen
ection.
I do not have a good explanation for why we have more women
n our series. I remember that there were also a substantial number
f women in Dr Miller’s series of 100 patients with subcentimeter
esions.
Dr Friedberg. Were there any complications from all those
eedle biopsies?
Dr Lee. Generally the main complication is a pneumothorax,
hich occurred in 2% or 3% of patients, requiring a small pigtail
atheter placed under fluoroscopy. I did not look at specifically
hich patients had a pneumothorax requiring a chest tube in this
eries. We have not had a patient requiring an operation as a
omplication of a needle biopsy.
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